Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and…mehr
This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a “must read” for all those involved in vaccine development, both in academia and industrial vaccine development.
Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines.- Viral-Vectored Vaccines to Control Pathogenic Filoviruses.- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention.- Current Status and Future of Polio Vaccines and Vaccination.- Current Status of Hantavirus Vaccines Development.- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses.- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines.- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines.- Radiovirotherapy for the Treatment of Cancer.- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer.- The Use of Oncolytic Herpesvirus for the Treatment of Cancer.- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.
Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines.- Viral-Vectored Vaccines to Control Pathogenic Filoviruses.- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention.- Current Status and Future of Polio Vaccines and Vaccination.- Current Status of Hantavirus Vaccines Development.- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses.- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines.- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines.- Radiovirotherapy for the Treatment of Cancer.- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer.- The Use of Oncolytic Herpesvirus for the Treatment of Cancer.- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.
Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines.- Viral-Vectored Vaccines to Control Pathogenic Filoviruses.- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention.- Current Status and Future of Polio Vaccines and Vaccination.- Current Status of Hantavirus Vaccines Development.- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses.- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines.- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines.- Radiovirotherapy for the Treatment of Cancer.- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer.- The Use of Oncolytic Herpesvirus for the Treatment of Cancer.- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.
Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines.- Viral-Vectored Vaccines to Control Pathogenic Filoviruses.- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention.- Current Status and Future of Polio Vaccines and Vaccination.- Current Status of Hantavirus Vaccines Development.- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses.- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines.- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines.- Radiovirotherapy for the Treatment of Cancer.- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer.- The Use of Oncolytic Herpesvirus for the Treatment of Cancer.- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
